Australian company Dimerix (ASX:DXB) has announced it has received firm commitments to raise $20 million via an institutional placement with proceeds to complete the ACTION3 Phase 3 clinical study in patients with debilitating kidney disease. …
Dimerix raises $20 million to continue and expand late-stage clinical trial of DMX-200
March 12, 2024 Australian Biotech
Latest Video
New Stories
-
NZ Government appoints former Deputy PM new chair of Pharmac
April 29, 2024 - - Latest News -
The listing will 'benefit thousands of Australian women', says Mark Butler
April 29, 2024 - - Latest News -
'An important first step to achieving reimbursed access for eligible patients in Australia'
April 28, 2024 - - Latest News -
The 'Week in Review' Podcast - 26 April
April 28, 2024 - - Podcast -
New research shows adult vaccination programs deliver major return on investment
April 26, 2024 - - Latest News -
Productivity Commission research backs the benefit of faster access to medicines
April 26, 2024 - - Latest News -
Let's make decisions based on credible information and not guesswork
April 24, 2024 - - Latest News